Price movement over the last 24 hours
ACADIA Pharmaceuticals Inc. vs Reddit Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Reddit Inc trades at $194.08 (market cap $38.39B). The key difference: Reddit Inc is far larger — about 8.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Reddit Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | RDDT | |
|---|---|---|
Market Cap | $4.49B | $38.39B |
Sector | Health | Media |
52-Week High | $28.06 | $270.71 |
52-Week Low | $20.06 | $121.84 |
Enterprise Value | $3.69B | $35.64B |
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Reddit (RDDT) trades at $200.67, up 3.13% today, reflecting strong momentum. The stock shows a bullish technical stance with moving averages aligned positively, though the RSI suggests potential overbought conditions. Fundamentally, the company exhibits robust revenue growth, with 2025 revenue at $2.2B and net income of $529.72M, supported by high gross margins of 91.37%. Recent earnings have mostly beaten expectations, and analyst sentiment is overwhelmingly positive with a consensus price target of $229.11. News highlights focus on AI safety initiatives and advertising growth.
The outlook for RDDT is favorable, driven by strong financial performance, expanding user engagement, and strategic AI investments. Key opportunities include sustained revenue growth and market share gains in social media. Risks involve competitive pressures, reliance on advertising revenue, and market volatility. With no sell ratings and solid cash flow generation, the stock presents a compelling case for growth-oriented investors, though valuation multiples remain elevated.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →